FDA's 2026 GLP-1 Warnings: 990 Reports and What They Mean for JoinSkinny Patients FDA has published ongoing warnings about compounded GLP-1 products generally: Dosing errors from measuring doses out of multi-dose vials Use of salt forms (like semaglutide sodium) that haven't been proven safe or effective Adverse events, including hospitalization in some cases As of May 31, 2026: 990 adverse-event reports tied to compounded semaglutide, and more than 730 tied to compounded tirzepatide - FDA notes these reports may be incomplete and don't, by themselves, establish that a compounded drug caused the reported event On April 30, 2026: FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list - a move that would close the main legal pathway for large-scale outsourcing-facility compounding of these drugs absent a shortage, with a public comment period that ran through June 29, 2026 These are industry-wide regulatory developments, not findings against JoinSkinny or any specific pharmacy named in this article

Rising Use of Obesity Medications Obesity remains a major global health issue
Common side effects include headache, nausea, and rare cases of organ toxicity or allergies
Pediatric bariatric surgeries among young people rose nearly 20% between 2020 and 2021, according to the most recent data
During a consultation, we can discuss what youre hoping to achieve and recommend a schedule that works best for your body and lifestyle
Traditional approaches, such as antibiotics, wound dressings, and surgical interventions, often show limited efficacy in addressing the underlying cellular dysfunctions that impair optimal healing